$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
Entrectinib’s new indications, effects and efficacy, usage and price description
2025-10-19 11:44:20
Check Details
How much does a box of dacomitinib 2023 cost?
2025-10-19 11:44:20
Check Details
Can cabozantinib be used to treat bone metastases?
2025-10-19 11:44:20
Check Details
Is dacomitinib effective in treating lung cancer with EGFR activating mutations?
2025-10-19 11:44:20
Check Details
Dacomitinib indications, effects, side effects and price description
2025-10-19 11:44:20
Check Details
Lorlatinib indications, dosage, efficacy, side effects and price
2025-10-19 11:44:20
Check Details
How much does a box of Afatinib 2023 cost?
2025-10-19 11:44:20
Check Details
How much does it cost to take afatinib for lung squamous cell carcinoma?
2025-10-19 11:44:20
Check Details
Which one has more side effects, afatinib or dacomitinib?
2025-10-19 11:44:20
Check Details
Detailed description of afatinib indications, usage and dosage, side effects, effects and efficacy
2025-10-19 11:44:20
Check Details
Comparative analysis of Iressa and Icotinib?
2025-10-19 11:44:20
Check Details
Which one is better, Iressa or Tarceva?
2025-10-19 11:44:20
Check Details
1
2
...
4107
4108
4109
4110
4111
4112
4113
...
4151
4152
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Trodelvy® (Sacituzumab Govitecan-hziy): A Life-Changing ADC for Advanced Cancers
2
A Revolutionary Targeted Therapy for Hematological Malignancies
3
A New Option for Advanced Renal Cell Carcinoma Treatment
4
Trametinib (Mekinist): Precision MEK1/2 Inhibition Transforming Cancer Care Short Description:
5
Pirtobrutinib: A Novel BTK Inhibitor Offering Hope for Hematologic Cancer Patients Short Description:
6
Sacituzumab Govitecan: Trop-2 Targeted ADC Clinical Medication Guide
7
Fulvestrant (Faslodex) Breast Cancer Guide: Indications, Dosage and Safety Specifications
8
Adagrasib (Krazati): Full Guide to KRAS G12C Inhibitor for Cancer Treatment
9
Comprehensive Analysis of the Third-Generation EGFR-TKI
10
ATOMIC Study: Atezolizumab Plus Chemo Improves DFS in dMMR Stage III Colon Cancer
11
Oncology Immunotherapy vs Anti-Inflammatory Biologic: Dostarlimab vs Secukinumab - A Mechanism-Centered Comparison
12
Third-Generation TKI Redefining Treatment for ALK+ & ROS1+ NSCLC